U.S. Biotechnology Market Trends and Recent Developments
U.S. Biotechnology Market Report Highlights
Technology Insights
DNA Sequencing: In 2023, DNA sequencing led the U.S. biotechnology market. This technology is vital across numerous fields, including medicine, where it aids in epidemiological research, illness diagnosis, and therapy. It holds the potential to revolutionize public health, plant and animal safety, food safety, and sustainable agriculture. DNA sequencing enhances agricultural efficiency through the breeding of disease-resistant plants and animals, ultimately reducing disease outbreaks. It also has the capacity to protect and improve human and wildlife habitats. DNA sequencing is crucial in genomics research, aiding in the interpretation of an organism's full genomic sequence and advancing our understanding of genomic structure and composition. It is instrumental in diagnosing and treating hereditary disorders, detecting microbial infections, and identifying tumorigenic gene alterations, thus supporting the development of personalized medicine. For instance, the National Institutes of Health's "All of Us Research Program" has made about 100,000 diverse whole genome sequences accessible, with 50% of the data representing historically underrepresented racial or ethnic groups in research. Nanobiotechnology: The nanobiotechnology segment is projected to grow at the fastest rate during the forecast period. Nanobiotechnology focuses on creating and modifying materials at the nanoscale, a field that is rapidly expanding with commercial applications. This technology has promising uses in regenerative medicine, drug delivery, and diagnostic medical testing.Application Insights
Healthcare: The healthcare segment dominated the U.S. biotechnology market and is expected to maintain its dominance throughout the forecast period. Biotechnology has significantly impacted the healthcare industry, transforming disease diagnosis, treatment, and prevention methods. Advances in molecular biology, genetics, and nanotechnology have enabled biotech companies and researchers to develop innovative drugs, vaccines, diagnostic tools, and other healthcare products. These advancements have led to new treatments for diseases like cancer and hereditary conditions, as well as the detection and treatment of infectious diseases such as HIV through novel antiretroviral drugs and diagnostic tools. For instance, in April 2024, Walgreens announced a collaboration with pharmaceutical companies to offer cell and gene therapies in the U.S., including a new licensed facility in Pittsburgh dedicated to these services. Additionally, Johnson & Johnson (J&J), a global healthcare organization, reported $85.2 billion in sales in 2023, with significant contributions from its Innovative Medicine and MedTech sectors. Bioinformatics: The bioinformatics segment is expected to grow at the fastest CAGR during the forecast period. Bioinformatics involves developing software and algorithms to extract knowledge from biological data, with applications in gene and proteome analysis, image analysis, drug discovery, and more. Precision and preventive medicine, which aim to develop strategies to avoid, manage, and treat dangerous infectious diseases, heavily rely on bioinformatics to improve our understanding of biological mechanisms. For instance, in July 2023, Bertis announced the launch of its Pan-omics Analysis Service & Solution (PASS) in the U.S. through its subsidiary, Bertis Bioscience Inc. PASS utilizes Bertis's expertise in pan-omics and in-house bioinformatics and AI technology to offer services such as protein identification, biomarker discovery, drug development, and clinical research.Recent Developments in the U.S. Biotechnology Market
- April 2024: Fresenius Kabi's Tyenne® became the first tocilizumab biosimilar approved by the FDA for intravenous and subcutaneous use. This biosimilar provides U.S. patients with a high-quality, affordable, and secure therapy option, building on its initial success in Europe.
- February 2024: AstraZeneca announced a $300 million investment in a state-of-the-art facility in Rockville, Maryland, to introduce its cell therapy platforms for crucial cancer studies and potential commercial supply. This facility is expected to create over 150 new jobs, primarily focused on T-cell treatment production, with the potential to expand to other disease areas in the future.
Get a Sample of this Report
U.S. Biotechnology Market
